

November 21, 2014 – October Investment Update 3 – By Jeffrey Hagenmeier



First up, is to once again to take another look at Gogo. It was recommended that you purchase the stock when it was listed for **\$16.31 USD** (United States Dollar) on **September 28<sup>th</sup>.** On **November 14<sup>th</sup>** the recommendation was made to continue to hold the stock. The share price at that time was \$17.88 USD. The stock is now listed for \$16.53 as of yesterday. The suggestion is once again to **continue to hold**. The **target** can still be set for \$19.00 USD for short term investors and

\$20.00 USD for medium term investors. Longer term investors may still look for \$22.00 USD. We may recommend a reduction in targets next week, if the stock has not moved much in price at that time.

Arch Coal is the next stock. Last week the recommendation was to continue to hold the stock. The original advice was to purchase shares in the company on**October 31<sup>st</sup>**. At that time the stock price was listed for \$2.09 USD. Yesterday the share price ended at \$2.53 USD. Last Friday, the stock had reached \$2.33 USD. The increase as yesterday of \$0.44 works out to be a 21.05% increase to date.Short term investors may wish to sell at this time. Medium and long term investors should set their targets



at\$3.00 and \$4.00 respectively. This is a \$1.00 reduction in the previous target levels. The recommendation is to sellas a short term investor. Medium and longer term investors should continue to hold the stock.



**\_\_\_\_\_\_**GOLDCORP Goldcorp is our third stock for today. It was listed for \$22.62 USD when the recommendation was made for purchase on October

**03**<sup>rd</sup>. Last Friday it had dipped to \$19.25. It was advised at that time that one should continue to hold the stock. Yesterday the stock was listed for \$20.61 USD. It is still down \$2.01 since the original acquisition, a loss of (8.89%). It was recommended as a long term investment, that is dependent on the increase of gold and silver prices in 2015. I am calling for a reduction in your target level however of \$2.00. Short term and



medium term investors should set their targets at **\$24.00 USD**. Longer term investors should set their target for **\$28.00 USD**. The recommendation at this point is to continue to hold the stock.

Amira Nature Foods is the next stock on our list. The stock was originally recommended for purchase as a longer term investment on October 27<sup>th</sup>. It was \$15.50 USD at that time. The stock ended at \$15.60 last Friday and yesterday it increased in price to \$16.00 USD after a \$0.76 increase which is the equivalent of 4.99% for the day. The stock is now up \$0 .50 or 3.23%. As a short term investor your target had been reached on October 30<sup>th</sup>. Those investors had been advised to set a target of \$17.05 USD. They were able to cash out with a\$1.55 advance or a 10% increase. Longer term investors



should still have their target set at **\$18.60 USD**, which will be a **20% increase** at this time. These investors should **continue to hold** the stock.



**BioCryst Pharmaceuticals** was a stock recommended to you on **October 24<sup>th</sup>**. The stock had been listed for **\$12.19 USD** on October 23rd. The following day the stock sold for **\$11.83 USD**. **Targets** were

recommended at the time, to be set for between**\$14.00** and **\$15.00 USD**. That would of allowed for a **20 to 25% increase** in the share price. Yesterday the stock was listed for **\$10.35 USD**. The stock is now down **\$1.48**. As the hype surrounding the Ebola virus has faded in the news, so has the enthusiasm for companies who do research on diseases and viruses in general. The fundamentals of this company are still positive, so the recommendation at this time, is **to continue to hold** shares in this company.

Our final update for October will be posted next Friday on November 28th.